Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies,…
$17.82+1.42%
报价 2026-11-06
市值
$1.88B
EV
$2.75B
PE (TTM)
–
预期 PE (FY2026)
5.8x
52 周区间距高点 -25.2%
$14.86$23.83
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
爆发潜力
2026-11-07不在筛选范围：industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| SRPTSarepta Therapeutics, Inc. | $1.88B | +1.4% | -3.6% | 58.6% | – | – | – | |
| IBRXImmunityBio, Inc. | $9.15B | +7.8% | +92.7% | 94.6% | – | – | – | |
| COGTCogent Biosciences, Inc. | $5.49B | +7.0% | +646.7% | 0% | – | – | – | |
| ADPTAdaptive Biotechnologies Corporation | $4.47B | +4.3% | +7.6% | 75.3% | – | – | – | |
| DNLIDenali Therapeutics Inc. | $3.21B | +1.8% | +1848.0% | 0% | – | – | – | |
| BEAMBeam Therapeutics Inc. | $2.73B | +2.1% | +81.1% | 100% | – | – | – | |
| RCUSArcus Biosciences, Inc. | $2.59B | +3.3% | -70.3% | 97% | – | – | – | |
| RXRXRecursion Pharmaceuticals, Inc. | $2.19B | +0.6% | -3.9% | -49.8% | – | – | – | |
| AGIOAgios Pharmaceuticals, Inc. | $1.76B | +4.0% | +160.7% | 87.9% | – | – | – | |
| 同行中位数 | – | – | +86.9% | 81.6% | – | – | – |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。
研究材料
电话会纪要摘要
暂无纪要摘要。